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Dietary compounds play an important role in the prevention and treatment of many cancers, although 
their specific molecular mechanism is not yet known. In the present study, thirty dietary agents 
were analyzed on nine drug targets through in silico studies. However, nine dietary scaffolds, such 
as silibinin, flavopiridol, oleandrin, ursolic acid, α‑boswellic acid, β‑boswellic acid, triterpenoid, 
guggulsterone, and oleanolic acid potentially bound to the cavity of PI3K‑α, PKC‑η, H‑Ras, and Ras 
with the highest binding energy. Particularly, the compounds silibinin and flavopiridol have been 
shown to have broad spectrum anticancer activity. Interestingly, flavopiridol was embedded in the 
pockets of PI3K‑α and PKC‑η as bound crystal inhibitors in two different conformations and showed 
significant interactions with ATP binding pocket residues. However, complex‑based pharmacophore 
modeling achieved two vital pharmacophoric features namely, two H‑bond acceptors for PI3K‑α, while 
three are hydrophobic, one cat‑donor and one H‑bond donor and acceptor for PKC‑η, respectively. 
The database screening with the ChemBridge core library explored potential hits on a valid 
pharmacophore query. Therefore, to optimize perspective lead compounds from the hits, which were 
subjected to various constraints such as docking, MM/GBVI, Lipinski rule of five, ADMET and toxicity 
properties. Henceforth, the top ligands were sorted out and examined for vital interactions with 
key residues, arguably the top three promising lead compounds for PI3K‑α, while seven for PKC‑η, 
exhibiting binding energy from − 11.5 to − 8.5 kcal  mol−1. Therefore, these scaffolds could be helpful in 
the development of novel class of effective anticancer agents.
Dietary compounds derived from plants have shown a wide range of application in cancer drug discovery, espe-
cially the consumption of fruits and vegetables preferably non-starchy such as broccoli, cabbage, spinach, kale, 
cauliflower, carrots, lettuce, cucumber, tomato, leek, rutabaga, and turnip contain potent bioactive compounds 
and have shown potent anticancer properties by exhibiting inhibitory effect on different  cancers1. The phyto-
chemicals such as alkaloids, monoterpenes, organo-sulfides, carotenoids, flavonoids, phenolic acids, stilbenes, 
and isoflavones have a direct impact on human health by playing a role in regulating chemo-preventive and 
chemo-therapeutic  approaches2, 3. Also, dietary compounds act as anticancer agents through various mecha-
nisms such as anti-proliferative, apoptosis, antioxidant, anti-metastasis, and angiogenesis, and by regulating 
vital metabolic pathways such as Wnt/β-catenin, PI3K/Akt/mTOR, MAPK (p38, JNK, and Erk1/2), peroxisome 
OPEN
1Department of Pathophysiology, The Key Immunopathology Laboratory of Guangdong Province, Shantou 
University Medical College, Xinling Road, Shantou 515041, Guangdong, China. 2Department of Organic and 
Biomolecular Chemistry, Ural Federal University, Ekaterinburg 620002, Russia. 3Department of Physiology, 
Shantou University Medical College, Shantou 515031, Guangdong, China. 4Department of Zoology, Sri 




Scientific Reports |        (2021) 11:12150  | https://doi.org/10.1038/s41598-021-90287-3
www.nature.com/scientificreports/
proliferator activator receptor gamma (PPAR-γ), Sonic Hedgehog, EGFR/Kras/Braf, EGFR, VEGFR, IGF1-R, 
TGF-β/Smad2/3, STAT1-STAT3, NF-кB, Nrf2, TNF-α, interleukins, COX-2, 5-LOX, and cyclin-CDK complexes, 
 respectively4–7. Given the importance of the dietary scaffolds, the National Cancer Institute (NCI) had conducted 
a chemo-preventive testing program for pre-clinical evaluation of over a thousand dietary agents with differ-
ent combinations in in vitro and in vivo studies since  19878, with over 40% of the tested compounds have been 
shown potent anticancer activity on many of the cancers; For example, breast, colon, prostate, and  lung9. Among 
these key scaffolds, Indole 3 carbinol is a well-known potent broad-spectrum agent tested for anticancer activity 
on breast, colorectal, cervical, and endometrial cancers. Also, it exhibits antiestrogenic activity by altering the 
cytochrome P450 based estradiol  metabolism10. Moreover, soy isoflavones, retinoids, vitamin E, organo-selenium, 
lycopene, perillyl-alcohol, and vitamin D1 scaffolds were shown prominent chemo-preventive profiles on prostate 
 cancer11, 12, notably, lycopene successfully entered phase I clinical trials. In addition, polyphenols, curcumin, 
and epigallocatechin gallate (EGCG) significantly reduced breast cancer, while curcumin and tea polyphenols 
showed anti-inflammatory and cyclooxygenase-2 inhibitory  activities13, 14. Resveratrol is a polyphenolic stilbene 
found abundantly in grape skin, which lessen the risk of cancer by targeting multiple signaling pathways; For 
example, the Wnt/β-catenin signaling  pathway15, 16. Pterostilbene is an essential bioactive constituent found in 
blueberries that inhibits breast cancer stem cell proliferation and metastasis by modulating NF-κB/microRNA 
 function17. Genistein, a soy isoflavone inhibits NF-κB by reducing the Hedgehog-GLI1 signaling pathway in both 
breast and prostate  cancers18. Natural isothiocyanates were isolated from cruciferous plants, which suppress cell 
proliferation and some key cellular signaling pathways such as, NF-κB, and  STAT319, 20. Phenethyl isothiocyanate 
(PEITC), a naturally occurring isothiocyanate, has been shown to inhibit colorectal cancer stem cell inhibition 
by suppression the Wnt/β-catenin pathway, reducing clonogenicity, self-renewal capacity, and  pluripotency21. 
Sulforaphane is a sulfur-rich compound that is important for targeting essential metabolic pathways such as Sonic 
hedgehog-GLI pathway, platelet-derived growth factor receptor-β, transcription factors, vascular endothelial 
growth factor and tumor size reduction in pancreatic  cancer22. Similarly, a diallyl trisulfide (DATS) derived 
from garlic is an organosulfur agent that prevent colorectal cancer by blocking the Wnt/β-catenin  pathways23. In 
virtue of these dietary scaffolds, which have broad-spectrum anticancer activity by targeting different signaling 
pathway, there is a pressing need to uncover relative drug targets to design inhibitors.
So far, various essential metabolic pathways and key factors have been accessed as a pool of potential thera-
peutic targets for the development of anticancer  therapies24, for example, transcription  factors25, 26, anti-apoptotic 
and pro-apoptotic proteins, protein kinases, cell cycle, and cell adhesion molecules, respectively. Among these 
key drug targets, phosphatidylinositol-3-kinase (PI3K) is a key target that is primarily affected by mutations 
in cancer, gene rearrangement, and gene amplification and is therefore an attractive drug  target27–31. In addi-
tion, Protein kinase C (PKC) is such a key signaling molecule, the dysregulation of which causes cancer and 
 diabetes32. Tumor receptor associate factor 2 (TRAF2) is a ring finger adaptor protein that plays a crucial role 
in the carcinogenicity, so it is another novel target but its role has not been properly  established33, 34. Nuclear 
transcription factor kappa B (NF-κB) is a well-known transcription factor with broad spectrum therapeutic 
profiles that regulates approximately 200 genes related to immune response, cell differentiation, cell proliferation, 
and  apoptosis35–39. Ras family proteins are small membrane-bound guanidine nucleotide-binding proteins that 
activate PI3K-α, AKT-mTOR, RAF-MERK-ERK, and RALGDS-RAL metabolic pathways and provide promis-
ing therapeutic  targets34, 40, 41. In view of importance of the dietary agents in treatment of cancer, Saldanha and 
Tollefsbol strongly implemented a study to identify and design novel cancer inhibitors with chemo-preventive 
properties along with specific drug  targets42. Therefore, the discovery of anticancer drugs based on the dietary 
scaffolds is a promising approach to prevent or inhibit cancer.
Results
Pocket volumetric analysis. The dietary compounds have been reported to have anticancer properties by 
exhibiting inhibition of an essential pathway and important factors such as transcription factors, anti-apoptotic 
and pro-apoptotic proteins, kinases, and adhesion molecules in cancer pathogenesis. Therefore, the drug targets 
such as PKC-η, HRas-P21, AKT-1, Ras, PI3K-α, MEKK3, NFκB-P52, MEKK2b, and TRAF2 were retrieved from 
the macromolecular database and examined for pocket volume, size, and shape (Fig. S2; Table S2). The volumet-
ric evaluation explained that the PI3K-α has a cohesive binding cavity by displaying a cavity volume of 2736.6 
Å as with a surface area of 2703 Å. The TRAF2 showed cavity volume of 1051 Å and the surface area of 662.5 Å. 
Likewise, the PKC-η revealed a cavity volume of 910.5 Å and a surface area of 843.6 Å. Similar binding pocket 
volumes 609.2 Å and 602.9 Å were shown by The MEKK2b and the AKT-1, while the surface area was recorded 
as 451.3 Å and 828.6 Å. The cavity volume exhibited by Ras protein was 593.8 Å and the surface area was 951.7 
Å. The MEKK3 has a pocket volume of 484.8 Å and a surface area of 332.6 Å. The NFκB and the HRas-P21 had 
small pocket volumes of 327.4 Å and 224.3 Å, respectively, while the surface area was 283.1 Å and 336.6 Å. This 
method of identifying the specific properties of the pocket shape and size of the targets help to classify selective 
dietary scaffolds that aid in the design of anticancer drugs and the elaboration of molecular mechanisms.
Dietary agents. 3D and 2D structures of dietary agents such as emodin, eugenol, gingerol, sulforaphane, 
linalool, catechin, oleanolic acid, ursolic acid, curcumin, yakuchinone-A, pinusolide, α-boswellic acid, olean-
drin, sesquiterpene lactone-326, resveratrol, triterpenoid, β-boswellic acid, anethole, capsaicin, glycolic acid, 
quercetin, genistein, ellagic acid, flavopiridol, zerumbone, garcinol, guggulsterone, parthenolide, halogenated 
monoterpenes, and silibinin have been successfully retrieved from PubChem with molecular formula, molecu-
lar weights and IUPAC structure identifiers (InChI and standard InChIKey) (Fig. S3). This was followed by the 
docking study on drug target to determine how these active principles form a molecular network by interfering 
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with a specific target, which promotes the molecular mechanism for further optimization of novel anticancer 
compounds.
Interactions of dietary agents with drug targets. Determining the molecular partners of the dietary 
agent’s in the cellular context is a necessary approach to evaluate molecular mechanisms for effective treat-
ment of cancer. To achieve this, therapeutic targets such as PKC-η, HRas-P21, AKT-1, Ras, PI3K-α, MEKK3, 
NFκB-P52, MEKK2b, and TRAF2 were subjected to docking studies to determine its molecular partner. Initially, 
the co-crystal ligands of the targets were extracted and the docking method was used to optimize the biologi-
cally relevant ligand binding conformation. For instance, the ligand PIK-108 is a propeller-shaped inhibitor and 
binds to the ATP binding pocket in the kinase domain of PI3K-α. However, the bound crystal ligand PIK-108 
was extracted and docked into the pocket which produced nine biologically relevant docked poses of the ligand 
and was found to be identical by overlaying with the crystal ligand. Subsequently, to verifies the docking method, 
the RMSD of the docked pose was calculated to be 0.8 Å, indicating that the docking is reliable, consistent, 
and reproducible. Additionally, the ligand molecular network unveiled the phenyl moiety was oriented in the 
specificity site  (Met772 and  Trp780) and gated by the  Met772 in the ATP pocket (Fig. S4). In the case of the dietary 
agents, the best binding energy have been found to be within − 9.0 to − 12.0 kcal  mol−1, as well as molecular 
contacts were identified such as H-bonds, hydrophobic forces, electrostatic interactions, and Pi–Pi interactions 
with pocket residues (Fig. 1 and Table S3). Silibinin (− 9.3), flavopiridol (− 9.2), oleandrin (− 10.3), ursolic acid 
(− 10.0), α-boswellic acid (− 10.2), β-boswellic acid (− 10.1), triterpenoid (− 10.6), guggulsterone (− 10.0), and 
oleanolic acid (− 10.0) showed the highest binding affinity with PI3K-α. In the case of the PKC-η, silibinin (− 
10.0), flavopiridol (− 10.1), oleandrin (− 9.2), ursolic acid (− 9.1), emodin (− 9.1), and ellagic acid (− 9.4) showed 
best binding energies. In addition, silibinin (− 10.2), flavopiridol (− 9.0), oleandrin (− 9.7), and α-boswellic acid 
(− 9.0) with the Ras, and silibinin (− 11.6) and glycolic acid (− 9. 3) compounds expressed substantial binding 
energies with the H-Ras, respectively. However, dietary compounds have provided the highest binding energy, 
but uncertainty with ligands has been observed due to unreliable binding poses, as well as interactions with 
pocket hotspot residues (Fig.  S5). Finally, a potent polyphenolic flavonoid silibinin was identified as broad-
spectrum inhibitory agent because it exhibited the highest binding energy and showed key interactions with 
H-Ras, PKC-η, Ras, and PI3K-α. The molecular interactions and superimposition studies suggest that silibinin 
binds to the ATP binding pocket of H-Ras, notably, it is shown to be identical to ATP. The silibinin-H-Ras com-
plex revealed that the hydroxy-methoxy phenyl was placed in the hinge region, the benzodioxane resided at the 
ribose site, and the phosphate site was occupied by the dihydrochromen (Fig. S6). In the case of silibinin- PKC-η 
complex, it showed six bonds: the 3, 7 hydroxyl, and 1O groups of the benzopyran bonded with  Asp497,  Val436, 
 Leu486, and the methoxyphenyl bonded with  Asp440, whereas in the case of Ras-silibinin complex, it has been 
shown to have bonds of 7-OH and 1O atoms of the benzopyran with  Lys317,  Phe228, and  Gly213, and the 1, 4 diben-
zodioxins and an OH groups with  Thr235. In addition, previous studies have reported a wide range of silibinin 
pharmacological activity, such as the STAT3  inhibitor66, anti-inflammatory, anti-PI3K-α and MAPK, cell cycle 
arrest at  G0/G1 phase and p38 MAPK  inhibitor67, 68, respectively. The silibinin have shown a broad-spectrum 
pharmacological effect on multiple drug targets and, therefore, can be utilized as a potential lead scaffold for 
further design of novel anticancer drugs with combined drug discovery and clinical study approach.
Flavopiridol is a semisynthetic flavoalkaloid derived from the chrome alkaloid Rohitukie. Strikingly, flavopiri-
dol has exerted significant two identical eloquent postures, as did the crystal ligand in the pockets of PI3K-α and 
PKC-η (Fig. 2). The PI3K-α isoform consists of two functional domains, the N-terminal and the C-terminal, and 
the ATP binding site is in the N-terminal domain with several sub-pockets: the adenine binding site  (Ile800,  Tyr836, 
 Phe930,  Met922), the hydrophobic site or the affinity pocket  (Tyr836,  Ile848,  Ile932,  Asp810) and the specificity site 
 (Met772 and  Trp780) is distinct in PI3K isoforms (Fig. 2A). However, flavopiridol formed critical interactions with 
ATP pocket of PI3K-α: two non-polar interactions were observed at the adenine binding site by the  Tyr836 and 
the chlorobenzene, and at the specificity site by the  Trp780 and the piperidine moiety. The 5-OH and 7-OH on the 
ring A formed polar interaction with  Met772 and  Asp933, as well as an O atom on the ring C and 3OH of piperidine 
with OH group of  Tyr836 and  Ile932 (Fig. 2B). Likewise, the molecular network of the PKC-η-flavopiridol complex 
has been described the chlorobenzene to be positioned at the adenine site by forming a non-polar contact with 
 Phe435 and a halogen bond with the backbone of  Val436. The A and C rings were inserted deep into the cavity and 
were able to form critical interactions with catalytic residues i.e.,  Lys384,  Asp497 and  Val369, and one Pi-Pi bond 
with  Phe366. The piperidine formed an amide bond with  Asp440 (Fig. 2C,D). Furthermore, the pharmacophore 
occupancy in the pockets of PI3K-α and PKC-η was described in the following section.
Furthermore, the Ras-flavopiridol complex revealed a non-polar contact of chlorobenzene with the  Phe228, a 
polar bond was formed by the  Asp319, the O-p bond was formed by 7-OH on the ring A and  Tyr232, respectively. 
Polar and hydrophobic contacts between catalytic residues  (Lys317 and  Ala218) and piperidine (3OH) have been 
identified. Hitherto, previous studies on flavopiridol had reported several therapeutic activities, such as anti-
tumor activity, by inhibiting the signal transduction pathway, as well as cyclin-dependent kinases (CDKs) as a 
strong binder, and induces apoptosis and anti-angiogenic activity in leukemic cells,  respectively69, 70. Particularly, 
flavopiridol has been approved as an orphan drug for chronic myeloid  leukemia71. Given these broad-spectrum 
pharmacological profiles of dietary agents as evidenced by acting on multiple targets, in this case the isoform-
selective inhibitors for PI3K-α and PKC-η were designed based on different scaffolds.
Complex based pharmacophore modeling. The pharmacophore modeling is a pioneering approach 
to drug discovery campaign, based primarily on physical–chemical features, shape, volume, and 3D alignment 
of the pocket. Pharmacophore is a combined steric and electronic descriptor of the drug, which has a specific 
inhibitory action on therapeutic targets. First and foremost, for a clear understanding of the pharmacophoric 
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properties of the active site, a pharmacophore map for the ATP binding pocket of PI3K-α was constructed, 
which revealed sixteen pharmacophores and represented in Fig. 3A. In addition, crystal structures of PI3K-α co-
crystalized with different ligand were downloaded from PDB (Table 1). The PLIF method summarized the cru-
cial interactions from the complexes using a fingerprint scheme, which reveals binding site residues interact with 
which parts of the ligands. In this scenario, the PLIF detects eleven key residues in the pocket, namely  Met772, 
 Ser774,  Lys802,  Asp810,  Tyr836,  Glu849,  Val851,  Ser854,  Gln859,  Met922 and  Ile932, respectively, interacting with different 
ligands (Fig. S7)72–74. The PLIF enable pharmacophore queries based on the frequencies of protein–ligand con-
tacts; therefore, two pharmacophore features such as F1 (Acc & ML) and F2 (Acc & ML) were generated by the 
PILF and these two features have been converted to the searchable pharmacophore query, respectively (Fig. 3B). 
The geometric distance and angle constraints of key pharmacophoric features on the 3D pharmacophoric map 
were calculated and overlaid with superposition of different ligands (Fig. 3C,D).
Figure 2.  (A) 3D position of the sub-pocket in the ATP binding site of PI3K-α and (B) Overlays of bound 
crystal ligand PIK-108 (green) and flavopiridol (yellow) at the ATP binding site of PI3K-α. (C). PKC-η is 
rendering ATP binding site with interaction potential including residues and (D) Overlays of bound crystal 
ligand naphthyridine (green) and flavopiridol (yellow) at the ATP binding site of the PKC-η. The proteins 
are shown in the cartoon and the key residues in the binding cavity indicate the sticks with labeling. Binding 
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Similarly, a pharmacophore map for the PKC-η was constructed, which exhibited thirteen pharmacophore 
features within the ATP binding pocket (Fig. 4A). However, to create the PLIF, two crystal structures were used, 
one complexed with 07U and the other docked complex with staurosporine. A PLIF reveals crucial contacts with 
hotspot residues, namely  Leu361,  Asp440,  Asp483,  Leu486,  Ala496 and  Asp497, and were represented by as a barcode 
and population in graphical mode (Fig. S8)75. Subsequently, the essential pharmacophore query has been resolved 
by using the PILF of PKC-η (Fig. 4B). Unambiguously, five key pharmacophoric features—Don  (F1), Cat & Don 
 (F2), Hyd  (F3), Hyd  (F4) and Hyd  (F5) have been identified to be interacted with hotspot residues and identified 
as a virtual filter to screen chemical library; in addition, the distance and angle limits of geometrically identified 
pharmacophoric features were measured on a 3D pharmacophoric map (Fig. 4C, D).
Figure 3.  . (A) 3D pharmacophore annotation of ATP binding pocket of PI3K-α, (B) Overlay of crystal 
structures of PI3K-α co-crystalized with different ligands and generated 3D spatial arrangement of 
pharmacophore features with vector projections in the binding cavity of PI3K-α, (C) The distance constraints 
were calculated between the vital features, and (D) The co-crystalized ligands of PI3K-α were superimposed and 
aligned with the generated pharmacophore query. The proteins are shown in the cartoon and the key residues 
in the binding cavity indicate the sticks with labeling and the ligands are indicated in red colour. (Don & Acc: 
hydrogen bond donor/acceptor, Aro: aromatic center, Don: hydrogen bond donor, Acc: hydrogen bond acceptor, 
Hyd: hydrophobic, Cat & Don: cation donor).
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Database screening. Virtual screening is a versatile approach to screen large chemical libraries by applying 
various filters, for instance, the pharmacophoric strategy of retrieving potential leads with specified therapeutic 
properties. The validated 3D pharmacophore query of PI3K-α and PKC-η was utilized to screen the refined 
ChemBridge database. Due to virtual screening 6048 pharmacophoric hits molecules were obtained for the 
PI3K-α and 4069 for the PKC-η and all possible pharmacophoric hits with that query pharmacophores by fit-
ting over the active pocket (Figs. 5A, 6A). In addition, the PLIF scheme summarizes the highest percentage 
of interaction between the ligands and the protein targets with 97% of virtual hits showing key contacts with 
hotspot residues of PI3K-α (Fig. 5B,C), whereas 17% hits were shown for PKC-η (Fig. 6B,C). However, to clas-
sify these perspective lead compounds from the pharmacophoric hits, which were further subjected to various 
constraints like docking, MM-GBVI, Lipinski rule of five, ADMET and toxicity properties. Henceforth, the top-
rank ligands were sorted out and provided complex interactions with key residues, unambiguously, the ten best 
promising lead compounds for PI3K-α, exhibiting binding energy from − 10.0 kcal  mol−1 to − 8.5 kcal  mol−1, 
thirteen compounds for PKC-η showed binding energy from − 11.5 kcal  mol−1 to − 8.9 kcal  mol−1, respectively 
(Table S4 and S5). 
Born interaction energies and binding affinities. The cohesive relationships of born interaction 
forces and binding affinities of the top-rank scaffolds were calculated using the generalized born/volume inte-
gral method available in MOE. Precisely, the binding affinity (kcal  mol−1) was calculated after minimization the 
energy of the complexes, resulting in three lead scaffolds for PI3K-α, seven selected for PKC-η (Tables 2 and 
3). Henceforth, the molecular network of complexes has been applied to detect implicated residues by tether 
restraint by 2D assessment, which excludes false positive due to presumption and default in docking proce-
dures along with scoring methods. Furthermore, significant 3D spatial alignment and significant molecular 
interactions of lead scaffolds were achieved with the pocket of PI3K-α and PKC-η. In the case of the PI3K-α, 
compound-1 showed the highest binding energy of − 10.5 kcal  mol−1 by exhibiting vital contacts such as the 2, 
3 dihydro-1H isoindole1 and the 3dione functional groups bound to an atom O of  Val850 and  Ile800, an N-atom 
forms a bond with  Trp780, a hydrophobic contact with  Tyr836 and one bond with  Val851, respectively. Chloroben-
zene displayed a hydrophobic contact with  Trp780. The carbonyl piperidine gave a hydrophobic interaction and 
showed a polar bond with the carbonyl of  Lys802, an N-atom bound to  Ile932, and the 4-OH interaction of piperi-
dine formed a bond with  Asp933 and  Met772 (Fig. 7a). Compound-2 exhibits binding energy of − 8.5 kcal  mol−1 
and forms seven bonds: two hydrophobic interactions with  Trp780 and  Tyr836, the isoquinoline and the benzodi-
oxol functional groups exhibit four bonds with  Tyr836,  Val851,  Ile932 and  Met772, the hydroxy-piperidine showing 
association with S-atom of  Met772 (Fig. 7b). The compound-3 displayed the binding energy of − 8.7 kcal  mol−1 
and formed nine binding interactions. The pyridine exhibited two bonds such as a polar and a hydrophobic 
contact with OH of  Tyr836. Oxygen atom bonds with  Ile832 and, 1, 4‐diazepan‐2‐one group formed three bonds 
with  Asp933,  Met772 and  Pro778. The phenyl group hydrophobically bound to  Trp780. The 4-hydroxy3-methoxy 
phenyl formed two bonds with  Ser774 and  Lys776 (Fig. 7c). In addition, pictilisib is a potent PI3K inhibitor, dis-
playing the binding energy of − 8.5 kcal  mol−1 and exhibiting eleven binding interactions with the ATP binding 
site residues of PI3K-α (Fig. 7d). The primidine formed four bonds: two hydrophobic interactions with  Tyr836 
and  Trp780 and two polar bonds with  Val850 and  Val851. The methyl sulfonyl group binds to  Asp933 and  Met772 and 
the 4-morpholinyl formed two binds to both  Met772 and  Ile800. The piperazinyl moiety exhibited two bonds with 
 Ile932 and  Met772.  
In contrast, an estimate of lead optimization revealed seven lead scaffolds for PKC-η and a molecular network 
with ATP binding residues. Compound-1 displayed the highest binding energy is − 10.0 kcal  mol−1 and the 
4-hydroxy phenyl group exhibited two bonds with  Phe435 and  Ala382, the carbonyl moiety bonded with  Leu486, 
the benzoxazepine-9-ol group bound with  Val369,  Lys384, and  Asp497, a hydrophobic bonding with  Phe366, and the 
benzothiazole showing polar bonding with  Asp440 have been observed (Fig. 8a). Similarly, compound-2 exhibited 
Table 1.  Crystal structures of PI3K-α and PKC-η co-crystalized with different ligands were downloaded from 
PDB.
S. No Crystal structures (PDB ID) Ligand Resolution Year
PI3K-α
1 4A55 PIK-108 3.5 Å 2011
2 4JPS (2S)-N ~ 1 ~ -{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide 2.20 Å 2014
3 5DXT (2S)-2-({2-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}oxy)propana-mide 2.25 Å 2016
4 5UBR 1-[4-(3-{4-amino-5-[1-(oxan-4-yl)-1H-pyrazol-5-yl]pyrrolo[2,1-f][1,2,4]triazin-7-yl}phenyl)piperazin-1-yl]ethan-1-one 2.40 Å 2017
5 6PYS (3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-1,3-dihydro-2H-indol-2-one 2.19 Å 2019
6 7K6M 2,2-difluoroethyl (3S)-3-{[2’-amino-5-fluoro-2-(morpholin-4-yl)[4,5’-bipyrimidin]-6-yl]amino}-3-(hydroxymethyl)pyrrolidine-1-carboxylate 2.41 Å 2021
PKC-η
1 3TXO 2-methyl-N ~ 1 ~ -[3-(pyridin-4-yl)-2,6-naphthyridin-1-;[yl]propane-1,2-diamine 2.05 Å 2011
2 3TXO Staurosporine 2.05 Å 2011
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the highest binding energy of − 9.9 kcal  mol−1 by exhibiting molecular contacts such as the hydrophobic bonding 
with  Val436,  Val369, and  Leu486 have been examined by the 1, 3 benzothiazoles, whereas the benzoxazepine-9-ol 
was found to bind to  Asp497 and  Phe366, and the amino group of cyclobutene carbonyl was found to bind to  Asp440, 
respectively (Fig. 8b). Compound-3, 4 and 5 showed the binding energy of − 9.4 kcal  mol−1, while compounds 
6 and 7 showed the binding energy of − 9.3 kcal  mol−1. However, compound-3 shows eight interactions—the 
dimethyl pyrazine formed a Pi-Pi bond with  Phe435 and a polar bond with the carboxylic group of  Val436, whereas 
the benzoxazepine displaying four bonds such as a pi-pi bond with  Phe366 as well as three polar bonds with  Val369, 
 Asp497 and  Asp440, and the hydroxy-benzoyl exhibit two bonds with  Asp440, respectively (Fig. 8c). Compound-4 
showed the highest binding interactions—the dimethyl pyrazine group was positioned at the adenine site and 
formed six bonds such as a Pi-Pi bonding with  Phe435 and five polar bonds with the backbones of  Val436 and 
 Val369 and so on with the side chains of  Ala382 and  Leu486. The benzoxazepine exhibited interactions with catalytic 
residues of  Lys384 and  Asp497, a Pi-Pi bond with  Phe366, and the 3‐hydroxy benzoyl showed two bonds: a polar 
bond with  Asp440 and a Pi-cationic bond with  Phe366 (Fig. 8d). Compound-5 formed twelve bonds: the hydroxy-
pyrrole was positioned at the adenine site and explicated bonds with the carboxylic group of  Val436, a Pi–Pi bond 
Figure 4.  (A) 3D pharmacophore annotation of ATP binding pocket of PKC-η, (B) Overlay of crystal 
structures of PI3K-η co-crystalized with different ligands and generated 3D spatial arrangement of 
pharmacophore features with vector projections in the binding cavity of PI3Kη, (C) The distance constraints 
were calculated between the vital features, and (D) The cocrystallized ligands of PKC-η were superimposed and 
aligned with the generated pharmacophore query. The proteins are shown in the cartoon and the key residues 
in the binding cavity indicate the sticks with labeling and the ligands are indicated in red colour. (Don & Acc: 
hydrogen bond donor/acceptor, Aro: aromatic center, Don: hydrogen bond donor, Acc: hydrogen bond acceptor, 
Hyd; hydrophobic, Cat & Don: cation donor).
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with  Phe436, and two bonds with the side chains of  Ala382 and  Leu486. The benzoxazepine showed five bonds such 
as four polar bonds with  Val369 and  Asp497, and a Pi-Pi bond with  Phe366, and the chloro-pyridine displayed two 
bonds with  Asp440 (Fig. 8e). Compound-6 showed eight bonds: the methyl phenyl group interacted with  Val436 
and showed a Pi-Pi bond with  Phe436. The benzoxazepine formed four bonds: two bonds with catalytic residues 
Figure 5.  . (A) The distance constraints of vital 3D pharmacophoric features were calculated and displayed in 
the ATP binding site of PI3K-α and Overlays of virtual hits in the ATP binding site of PI3K-α including vector 
projections. The PLIF computed the interactions between the PI3Kα-virtual, (B) the barcode representation 
of fingerprint of the PI3K-α-ligand complexes: The x-axis displays a three-letter code of the key residues and 
the y-axis shows the number of PI3K-α ligand complexes, and (C) population mode refers to the histogram of 
fingerprint of the virtual hits showing the number of ligands with which each residue interacts.
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of  Lys384 and  Asp497, and a Pi–Pi bond with  Phe366. The hydroxy methoxy pyridine formed three bonds with 
 Asp440 (Fig. 8f). Compound-7 disclosed seven interactions: the 2-hydroxyphenyl was positioned at the adenine 
pocket and formed two polar bonds with  Leu486 and  Ala382 and a Pi–Pi bond with  Phe436. The 4-hydroxy phenyl 
Figure 6.  . (A) The distance constraints of vital 3D pharmacophoric features were calculated and displayed 
in the ATP binding site of PKC-η and Overlays of virtual hits in the ATP binding site of PKC-η including 
vector projections. The PLIF computed the interactions between the PKC-η PKC-η -virtual, (B) The barcode 
representation of fingerprint of the PKC-η-ligand complexes: The x-axis displays a three-letter code of the key 
residues and the y-axis shows the number of PKC-η-ligand complexes, and (C) Population mode refers to the 
histogram of fingerprint of the virtual hits showing the number of ligands with which each residue interacts.
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propane formed complex interactions with catalytic residues of  Lys384 and  Asp440, while the bi-pyrazine formed 
a polar bond with  Asp440 and a Pi-Pi bond with  Phe366 (Fig. 8g). In addition, the reference drug staurosporine is 
a natural alkaloid and ATP antagonist, which deeply occupied at the ATP binding site by releasing the binding 
energy of − 8.5 kcal  mol−1 and showed five polar and a non-polar interaction, respectively (Fig. 8h). An oxygen 
atom of lactam formed one polar interaction with  Val436, Nitrogen atom of triazocyclo noncosa formed two 
bonds with  Val369 and one non-polar contact with  Phe366, methoxy of tetrahydropyran exhibited one bond with 
 Leu486 and methylamine bonded with  Asp440, respectively.
Drug‑likeness and toxicity properties. The molecular properties of the drug, pharmacodynamics, 
pharmacokinetics, ADMET, and toxic properties play a crucial role in bioavailability. Therefore, the identified 
isoform selective lead scaffolds were evaluated using a FAF-Drugs server (Fig. 9; Table 4). Basically, the pharma-
codynamics properties revealed promising molecular interactions with decisive residues of the pocket. Lipinski’s 
rule: molecular weight, cLogP, hydrogen bond acceptors and donors were measured in relation to the physico-
chemical and the pharmacokinetic properties of the leads. The molecular weight was estimated to be less than 
500 (≤ 500) and the cLogP or partition coefficient plays a major role in accessing the drug in the body and was 
predicted to be less than five (≤ 5) indicating appropriate absorption and distribution properties. In addition, 
H-bond acceptors were found to be less than ten (≤ 10), while H-bond donors were less than five (≤ 5), resulting 
in the lead compounds obeyed the rule of five. Furthermore, it has been revealed that absorption capacity was 
soluble and moderately soluble by estimating the solubility in water. Estimation of interactions with skin perme-
ability, gastrointestinal absorption, blood–brain barrier (BBB), and with different cytochrome p450 isoforms 
Table 2.  2D structures, IUPAC name, binding interactions, efficiency, binding energy, binding affinity, and 
MM/GBVI of the best lead molecules of PI3K-α.
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Table 3.  2D structures, IUPAC name, binding interactions, efficiency, binding energy, binding affinity, and 
MM/GBVI of the best lead molecules of PKC-η.
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were particularly involved in drug elimination. Furthermore, drug-likeness depends mainly on the molecular 
features of the compounds and was compatible with ADMET in the body. Also, oral drug administration is a sys-
tematic route of delivering drug to pharmacologically active drugs, therefore; Oral bioavailability was assessed 
by evaluating the Veber rule, Egan rule, and Bayer oral PhysChem score, indicating reliable ADME properties 
approved as oral drug administration. Importantly, drug safety profiles were assessed by GSK 4/400 rule, Pfizer 
3/75 rule, and phospholipidosis non-inducer, which are non-toxic profiles. Given the leads drug-likeness prop-
erties, further comprehensive pharmacological evaluations are recommended to hopefully ensure anticancer 
properties for effective clinical management of cancer. 
Materials and methods
Protein preparation. Crystal structures of PKC-η (PDB ID: 3TXO)43, HRas-P21 (PDB ID: 121P)44, AKT-1 
(PDB ID: 3CQW)45, Ras (PDB ID: 1LFD)46, PI3K-α (PDB ID: 4A55)47, MEKK3 (PDB ID: 2PPH)48, NFκB-P52 
(PDB ID: 1A3Q)49, MEKK2b (PDB ID: 2CU1)50 and TRAF2 (PDB ID: 3M06)51 were retrieved from Protein 
Data Bank (PDB). However, identification of missing regions in the crystal structures was accomplished with 
SEQATOMs (Fig. S1; Table S1)52. Five missing regions have been found in crystal structure of PI3K-α (4A55): 
region-I (M1-R32), region-II (R309-S323), region-III (V409-C420), region-IV (V500-N526) and region-V 
(C862-Q871), respectively. These missing regions were built based on 5SXA (PDB ID)53. The missing regions 
were found away from the active pocket. A missing region (C506-G516) was identified in crystal structure of 
PKC-η and was built from PDB ID: 3TXO. Subsequently, homology modeling was carried out for missing resi-
dues using MOE. Water molecules, cofactors, and bound ligands were extracted and energy was minimized with 
the molecular operating environment (MOE) using the following methods and parameters. Hydrogens were 
Figure 7.  . Binding mode, interactions of (a) Compound-1, (b) Compound-2, (c) Compound-3 and (d) 
Pictilisib (GDC-0941 (reference inhibitor)) at the ATP binding pocket of PI3K-α. The protein (cyan) is shown in 
the cartoon with the surface model, the active site residues are indicated in sticks with labeling and the binding 
interactions are indicated in red dotted lines with distances (Å).
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added and the gradient was set to 0.00001. The force field of the MMFF94x was set up with the cut off value 
enabled from 8 to 10, the solvation was set to distance mode, the exterior was set to 8, the dielectric was set to 1, 
and furthermore, the partial charges have been fixed for the required calculations. After energy minimization, 
the proteins were successfully utilized for further studies.
Pocket volumetric analysis. Binding pockets, size, shape, key residues, and pocket opening of drug tar-
gets were analyzed using a CASTp (Computed Atlas of Surface Topography of proteins)  server54.
Ligand preparation. The 3D atomic coordinates of the dietary agents were retrieved from PubChem. In 
addition, the molecular formulas, molecular weights, and IUPAC structure identifiers (InChI and standard 
InChIKey) were successfully retrieved, along with a core library consists of 735,000 diverse scaffolds available in 
ChemBridge (https:// www. chemb ridge. com/ index. php). Furthermore, to avoid errors in compound structures, 
for instance, single bonds, protonation, disordered bond lengths, tautomers, ionization states, and explicit coun-
ter ions, in this connection, the database was launched into MOE to remove faulty structures by washing. Energy 
minimization was achieved with 3D optimization of small molecules and the addition of hydrogens and atomic 
partial charges with MMFF94x  forcefield55. Finally, the refined small molecules were examined in subsequent 
studies.
Figure 8.  . Binding mode, interactions of (a) Compound-1, (b) Compound-2, (c) Compound-3 and (d) 
Compound-4, (e) Compound-5, (f) Compound-6, (g) Compound-7, and (h) Staurosporine (reference 
inhibitor) at the ATP binding pocket of PKC-η. The protein (light blue) is shown in the cartoon with the surface 
model, the active site residues are indicated in sticks with labeling and the binding interactions are indicated in 
red dotted lines with distances (Å).
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Figure 9.  . 2D structure, drug-likeness, compound complexity, oral property space, oral absorption estimation, 
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Molecular docking. Molecular docking studies using Autodock Vina 4.0 with a PyRx interface have 
been conducted between dietary agents and cancer  targets56. The docking parameters were set as follows: The 
Lamarckian genetic algorithm was used as the docking program by setting the window size 10.057, and the 
number of individuals in the population was set to 150. The maximum number of energy evaluations and the 
maximum number of generations was set to 25,000 and 27,000. For the survival of next-generation, the top 
individual was set to 1. The gene mutation rate was set to 0.02. The crossover rate was set to 0.8, and the cauchy 
beta was 1.0. Accordingly, the grid was set according to the binding pocket and the exhaustiveness was set to 8. 
After docking simulations, the binding energy cutoff was set between 3.0 and 11.0 kcal/mol. Bond angles, bond 
lengths, and hydrogen bonding interactions were analyzed using  PyMOL58 and electrostatic bond distance was 
set to between 3.0–5.0 Å, the hydrophobic bond was set to range 3.0–5.0 Å, and the hydrogen bond was set to 
between 2.8 and 4.0 Å.
Pharmacophore modeling and virtual screening. Crystal structures of PI3K-α and PKC-η co-crys-
talized with various ligands resolved at high resolution were retrieved from PDB. However, the protein ligand 
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available in MOE. Additionally, it also generates a set of pharmacophore query features from the annotation 
point of the receptor-ligand complex. These pharmacophore features include a significant group or group of 
H-donors (Don), H-acceptors (Acc), aromatic centers (Aro), Hydrophobic (Hyd), donor and acceptor (Don & 
Acc), R-groups and bioisosteres, respectively. The generated pharmacophore query contains a set of constraints 
and features. In MOE, potential setup was used to generate forcefield parameters. The force field was set to 
amber10: EHT and the solvation was set to R-field. Numerous molecular interactions such as van der Waals 
forces, electrostatic, and restrains have been enabled. Hydrogens and partial chargers were added. The recep-
tor strength was tethered to 5000 to keep the receptor rigid and this allows 3D protonation and removes water 
molecules from the receptor or the ligand within 4.5 Å. The scheme was set to EHT to construct the pharmaco-
phore query from the ligand annotation points. The annotation points were indicated in various colors, green 
for hydrophobic, purple for hydrogen bond donor, cyan for hydrogen bond acceptor, and orange for aromatic. 
Subsequently, the generated pharmacophore query was verified and improved by repeating the pharmacophoric 
feature search iteratively by changing the features. To obtain potential leads, the pharmacophore features were 
reduced according to catalytic residues in the cavity for selective binding and orientations. A virtual screening 
(VS) is important approach in computer-aided drug design to screen a huge chemical  library59. In this study, 
pharmacophore-based virtual screening was used to screen a refined ChemBridge database using a modified 
and validated pharmacophore queries. Consequently, retrieved hits with minimal binding energy conformations 
were saved in a separate MOE database using the conformation import method. Since then, the conformers of 
each ligand have been filtered through recognizable pharmacophoric features, which can be considered as a 
potential virtual hit. Therefore, the best hits in the developed pharmacophore model were identified, mapped 
and further assessed with docking simulation.
Born interaction energies and binding affinities. The binding affinity of the lead molecules was cal-
culated using general born-volume integral (MM/GBVI) implicit solvent methods implemented in  MOE60–63. 
According to the Eq. (1), the interactions energy (IE) is defined as the energy difference between the enzyme–
substrate complex (E–S) and individual enzyme (E) and substrate (S).
Born interaction energy describes non-bonded contacts between the ligand and the protein by means of 
molecular interactions such as van der Waals, coulomb electrostatic, and solvent interactions. The strain ener-
gies and solvent molecules of the ligand and the protein were ignored during binding affinity evaluations. For 
the binding affinity calculations, the London scoring method was represented in kcal  mol−1 units. To discourage 
gross movements, the active site residues and the ligand molecules were kept flexible whereas the active site was 
kept rigid to tether restraints. Furthermore, the binding affinity of the protein–ligand complex was calculated 
after the completion of energy minimization.
Drug‑likeness and toxicity property predictions. Lipinski rule of five such as molecular weight 
(< 500), H-bond acceptor (< 10), H-bond donor (< 5) and cLogP (< 5), toxic properties: mutagenic, tumorigenic, 
irritant and reproductive effects and ADMET (absorption, distribution, metabolism, excretion, and transport) 
properties were assessed using the FAF-Drugs server and the Swiss-ADME64, 65.
Conclusion
Dietary compounds have potent anticancer properties and play a pivotal role in the prevention or treatment 
of cancer; however, the design of novel potent anticancer drugs require a specific molecular mechanism of the 
dietary compounds. In the current study, several dietary compounds have been subjected to docking stud-
ies against cancer therapeutic targets unveiled that naturally occurring dietary agents—silibinin, flavopiridol, 
oleandrin, ursolic acid, α-boswellic acid, β-boswellic acid, triterpenoid, guggulsterone, and oleanolic acid have 
been shown to have broad-spectrum anticancer properties by exhibiting inhibition against different cell signaling 
pathways. Importantly, silibinin and flavopiridol have significantly demonstrated broad-spectrum anticancer 
activity by targeting numerous drug targets—PI3K-α, PKC-η, H-Ras, and Ras. Interestingly, flavopiridol was 
embedded in the pockets of PI3K-α and PKC-η as bound crystal inhibitors and described critical interactions 
with hotspot residues. This prompted the designing of isoform inhibitors based on potent scaffold of various 
PI3K-α and PKC-η inhibitors using complex-based pharmacophore modeling. Finally, the top three optimistic 
lead compounds for PI3K-α, while seven for PKC-η from the top ligands were sorted and examined for impor-
tant interactions with key residues. In addition, drug safety profiles, Lipinski rule, ADMET, pharmacokinetics, 
drug-likeness and toxic studies proposed for further validations by scaffold chemical synthesis and therapeutic 
(1)IE = EE−S − (EE + ES)
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Molecular weight: 582.13 
g/mol
Num. heavy atoms: 41
Num. arom. heavy 
atoms: 15
Fraction Csp3: 0.53
Num. rotatable bonds: 5
Num. H-bond accep-
tors: 5




Log Po/w (iLOGP): 4.47
Log Po/w (XLOGP3): 
4.66
Log Po/w (WLOGP): 
4.69
Log Po/w (MLOGP): 
3.06
Log Po/w (SILICOS-IT): 
3.93
Consensus Log Po/w 
: 4.16
Log S (ESOL): -6.33
Solubility: 2.75e-04 mg/
ml ; 4.72e-07 mol/l
Class: Poorly soluble
Log S (Ali): -6.45
Solubility: 2.05e-04 mg/
ml ; 3.52e-07 mol/l
Class: Poorly soluble
Log S (SILICOS-IT): 
-6.40
Solubility: 2.30e-04 mg/










Log Kp (skin permea-
tion): -6.54 cm/s
Lipinski: Yes; 1 violation: 
MW > 500
Ghose: No; 3 violations: 








Leadlikeness: No; 2 






Molecular weight: 465.58 
g/mol
Num. heavy atoms: 34
Num. arom. heavy 
atoms: 12
Fraction Csp3: 0.48
Num. rotatable bonds: 8
Num. H-bond accep-
tors: 6
Num. H-bond donors: 1
Molar Refractivity: 
140.50
TPSA : 75.13 Å2
Log Po/w (iLOGP): 4.24
Log Po/w (XLOGP3): 
3.47
Log Po/w (WLOGP): 
2.85
Log Po/w (MLOGP): 
1.56
Log Po/w (SILICOS-IT): 
3.60
Consensus Log Po/w 
: 3.14
Log S (ESOL): -4.65
Solubility: 1.05e-02 mg/
ml ; 2.26e-05 mol/l
Class: Moderately soluble
Log S (Ali): -4.73
Solubility: 8.67e-03 mg/
ml ; 1.86e-05 mol/l
Class: Moderately soluble
Log S (SILICOS-IT): 
-5.75
Solubility: 8.30e-04 mg/










Log  Kp (skin permea-
tion): -6.68 cm/s
Lipinski: Yes; 0 violation








Leadlikeness: No; 2 






Molecular weight: 461.56 
g/mol
Num. heavy atoms: 34
Num. arom. heavy 
atoms: 17
Fraction Csp3: 0.42
Num. rotatable bonds: 7
Num. H-bond accep-
tors: 6
Num. H-bond donors: 1
Molar Refractivity: 
136.27
TPSA : 83.72 Å2
Log  Po/w (iLOGP): 2.88
Log  Po/w (XLOGP3): 1.79
Log  Po/w (WLOGP): 1.42
Log  Po/w (MLOGP): 1.27
Log  Po/w (SILICOS-IT): 
2.61
Consensus Log  Po/w : 1.99
Log S (ESOL): -3.74
Solubility: 8.45e-02 mg/
ml ; 1.83e-04 mol/l
Class: Soluble
Log S (Ali): -3.17
Solubility: 3.14e-01 mg/
ml ; 6.81e-04 mol/l
Class: Soluble
Log S (SILICOS-IT): 
-5.91
Solubility: 5.73e-04 mg/










Log  Kp (skin permea-
tion): -7.84 cm/s
Lipinski: Yes; 0 violation







Brenk : 0 alert
Leadlikeness; No; 1 






Molecular weight: 513.64 
g/mol
Num. heavy atoms: 35
Num. arom. heavy 
atoms: 18
Fraction Csp3: 0.43
Num. rotatable bonds: 5
Num. H-bond accep-
tors: 8




Log  Po/w (iLOGP): 3.01
Log  Po/w (XLOGP3): 1.62
Log  Po/w (WLOGP): 1.93
Log  Po/w (MLOGP): 0.94
Log  Po/w (SILICOS-IT): 
2.57
Consensus Log  Po/w : 2.01
Log S (ESOL) : -4.10
Solubility: 4.12e-02 mg/
ml ; 8.02e-05 mol/l
Class : Moderately 
soluble
Log S (Ali): -4.26
Solubility: 2.82e-02 mg/
ml ; 5.50e-05 mol/l
Class : Moderately 
soluble
Log S (SILICOS-IT) : 
-6.12
Solubility: 3.91e-04 mg/
ml ; 7.60e-07 mol/l
Class : Poorly soluble
GI absorption: Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -8.28 cm/s
Lipinski: Yes; 1 violation: 
MW > 500
Ghose : No; 2 violations: 
MW > 480, MR > 130
Veber : No; 1 violation: 
TPSA > 140





PAINS : 0 alert
Brenk : 0 alert
Leadlikeness : No; 1 






Molecular weight: 418.47 
g/mol
Num. heavy atoms: 30
Num. arom. heavy 
atoms: 21
Fraction Csp3: 0.13
Num. rotatable bonds: 3
Num. H-bond accep-
tors: 5
Num. H-bond donors: 2
Molar Refractivity: 
119.78
TPSA : 111.13 Å2
Log  Po/w (iLOGP) : 3.05
Log  Po/w (XLOGP3) 
: 4.58
Log  Po/w (WLOGP) : 3.88
Log  Po/w (MLOGP) : 2.31
Log  Po/w (SILICOS-IT) 
: 4.50
Consensus Log  Po/w : 3.66
Log S (ESOL) : -5.64
Solubility: 9.59e-04 mg/
ml ; 2.29e-06 mol/l
Class : Moderately 
soluble
Log S (Ali) : -6.64
Solubility: 9.64e-05 mg/
ml ; 2.30e-07 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : 
-6.62
Solubility: 1.02e-04 mg/
ml ; 2.43e-07 mol/l
Class : Poorly soluble
GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -5.60 cm/s







PAINS : 0 alert
Brenk : 0 alert
Leadlikeness : No; 2 











properties Lipophilicity Water solubility Pharmacokinetics Drug likeness Medicinal chemistry
2
Formula: C21H21N3O3S
Molecular weight: 395.47 
g/mol
Num. heavy atoms: 28
Num. arom. heavy 
atoms: 15
Fraction Csp3: 0.33
Num. rotatable bonds: 3
Num. H-bond accep-
tors: 5
Num. H-bond donors: 2
Molar Refractivity: 
112.91
TPSA : 116.92 Å2
Log  Po/w (iLOGP) : 3.04
Log  Po/w (XLOGP3) 
: 2.52
Log  Po/w (WLOGP) : 2.74
Log  Po/w (MLOGP) : 1.83
Log  Po/w (SILICOS-IT) 
: 3.89
Consensus Log  Po/w : 2.80
Log S (ESOL): -4.08
Solubility: 3.30e-02 mg/
ml ; 8.36e-05 mol/l
Class : Moderately 
soluble
Log S (Ali): -4.62
Solubility: 9.45e-03 mg/
ml ; 2.39e-05 mol/l
Class : Moderately 
soluble
Log S (SILICOS-IT) : 
-5.43
Solubility: 1.46e-03 mg/
ml ; 3.70e-06 mol/l
Class : Moderately 
soluble
GI absorption: High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -6.92 cm/s







PAINS : 0 alert
Brenk : 0 alert
Leadlikeness : No; 1 





Molecular weight: 392.40 
g/mol
Num. heavy atoms: 29
Num. arom. heavy 
atoms: 18
Fraction Csp3: 0.18
Num. rotatable bonds: 3
Num. H-bond accep-
tors: 6
Num. H-bond donors: 3
Molar Refractivity: 
111.39
TPSA : 103.12 Å2
Log  Po/w (iLOGP) : 1.90
Log  Po/w (XLOGP3) 
: 3.36
Log  Po/w (WLOGP) : 2.68
Log  Po/w (MLOGP) : 1.58
Log  Po/w (SILICOS-IT) 
: 2.90
Consensus Log  Po/w : 2.48
Log S (ESOL) : -4.65
Solubility: 8.76e-03 mg/
ml ; 2.23e-05 mol/l
Class : Moderately 
soluble
Log S (Ali) : -5.20
Solubility: 2.46e-03 mg/
ml ; 6.26e-06 mol/l
Class : Moderately 
soluble
Log S (SILICOS-IT) : 
-5.50
Solubility: 1.23e-03 mg/
ml ; 3.13e-06 mol/l
Class : Moderately 
soluble
GI absorption: High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -6.31 cm/s








Brenk : 0 alert
Leadlikeness: No; 1 





Molecular weight: 391.42 
g/mol
Num. heavy atoms: 29
Num. arom. heavy 
atoms: 18
Fraction Csp3: 0.23
Num. rotatable bonds: 3
Num. H-bond accep-
tors: 6
Num. H-bond donors: 2
Molar refractivity: 112.12
TPSA : 95.78 Å2
Log  Po/w (iLOGP) : 2.41
Log  Po/w (XLOGP3) 
: 2.23
Log  Po/w (WLOGP) : 2.67
Log  Po/w (MLOGP) : 0.91
Log  Po/w (SILICOS-IT) 
: 3.34
Consensus Log  Po/w : 2.31
Log S (ESOL) : -3.93
Solubility: 4.57e-02 mg/
ml ; 1.17e-04 mol/l
Class : Soluble
Log S (Ali) : -3.88
Solubility: 5.20e-02 mg/
ml ; 1.33e-04 mol/l
Class : Soluble
Log S (SILICOS-IT) : 
-6.10
Solubility: 3.14e-04 mg/
ml ; 8.02e-07 mol/l
Class : Poorly soluble
GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -7.10 cm/s







PAINS : 0 alert
Brenk : 0 alert
Leadlikeness : No; 1 





Molecular weight: 404.46 
g/mol
Num. heavy atoms: 30
Num. arom. heavy 
atoms: 18
Fraction Csp3: 0.26
Num. rotatable bonds: 6
Num. H-bond accep-
tors: 5
Num. H-bond donors: 2
Molar Refractivity: 
121.13
TPSA : 89.79 Å2
Log  Po/w (iLOGP) : 2.15
Log  Po/w (XLOGP3) 
: 2.14
Log  Po/w (WLOGP) : 2.00
Log  Po/w (MLOGP) : 1.26
Log  Po/w (SILICOS-IT) 
: 2.36
Consensus Log  Po/w : 1.98
Log S (ESOL) : -3.74
Solubility: 7.29e-02 mg/
ml ; 1.80e-04 mol/l
Class : Soluble
Log S (Ali) : -3.66
Solubility: 8.90e-02 mg/
ml ; 2.20e-04 mol/l
Class : Soluble
Log S (SILICOS-IT) : 
-5.64
Solubility: 9.31e−04 mg/
ml ; 2.30e−06 mol/l
Class : Moderately 
soluble
GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor: No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -7.25 cm/s







PAINS : 0 alert
Brenk : 0 alert
Leadlikeness : No; 1 





Molecular weight: 392.45 
g/mol
Num. heavy atoms: 29
Num. arom. heavy 
atoms: 18
Fraction Csp3: 0.26
Num. rotatable bonds: 4
Num. H-bond accep-
tors: 6
Num. H-bond donors: 2
Molar Refractivity: 
115.43
TPSA : 75.05 Å2
Log  Po/w (iLOGP) : 3.57
Log  Po/w (XLOGP3) 
: 3.21
Log  Po/w (WLOGP) : 3.19
Log  Po/w (MLOGP) : 1.59
Log  Po/w (SILICOS-IT) 
: 3.90
Consensus Log  Po/w : 3.09
Log S (ESOL) : -4.49
Solubility: 1.27e-02 mg/
ml ; 3.23e-05 mol/l
Class : Moderately 
soluble
Log S (Ali) : -4.46
Solubility: 1.37e-02 mg/
ml ; 3.48e-05 mol/l
Class : Moderately 
soluble
Log S (SILICOS-IT) : 
-6.66
Solubility: 8.51e-05 mg/
ml ; 2.17e-07 mol/l
Class : Poorly soluble
GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log  Kp (skin permeation) 
: -6.41 cm/s








Brenk : 0 alert
Leadlikeness : No; 1 
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evaluations. Accordingly, the drug targets have been identified for future research, which can be considered with 
its dietary agents to develop novel therapeutic approaches with better efficacy, specificity, and effective treatment 
of cancer pathogenesis without any side effects.
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